Labiotech.eu

News and Trends 10 Oct 2018

Cancer Immunotherapy Phase I on Hold After Patient Death

The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […]

October 10, 2018 - 2 minutesmins - By Jonathan Smith

More News! 10 Oct 2018

This Test Can Detect Four Drugs With Just a Fingerprint

The British company Intelligent Fingerprinting has shown that its non-invasive fingerprint drug test can yield results comparable to blood tests in just 10 minutes. The technology, developed at the University of East Anglia, can detect extremely low amounts of amphetamines, cannabis, cocaine and opiate drugs from the sweat of a single fingerprint. The sample is […]

October 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 10 Oct 2018

How to Make Industrial Biotech Pay

Making enough money to survive long enough to get a product to market can be tough for any biotech, but even more so for companies operating in the industrial space, where it can be less easy to predict development time and potential financial returns. At our recent Refresh event in Paris, Emmanuel Petiot, CEO of […]

October 10, 2018 - 5 minutesmins - By Helen Albert

News and Trends 9 Oct 2018

Slow-Release Drug Biotech IPO Raises €30M

The French biotech MedinCell, an injectable slow-release drug specialist, has received a shot of success as its IPO raises €30M in the Euronext stock exchange in Paris. MedinCell is hoping to improve patient compliance with medication regimes by injecting them with a drug-infused gel. Patient compliance with taking medication can be as low as 30% […]

October 9, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 9 Oct 2018

Hormone Therapy for Inherited Hormonal Disorder Fails at Phase III

A European Phase III trial has become a major stress for British biotech Diurnal. Its specially designed hormone therapy was no better than conventional therapies in treating an inherited hormonal disorder. Congenital adrenal hyperplasia is a rare genetic condition where patients lack crucial enzymes for making hormones. The most common form lacks 21-hydroxylase, the enzyme […]

October 9, 2018 - 3 minutesmins - By Jonathan Smith

In Depth 9 Oct 2018

How to Capitalize on Opportunities in Underserved Disease Areas

Developing treatments for underserved diseases can be surprisingly profitable for biotechs, we asked the experts to tell us more about how best to exploit these areas. We hear a lot about cancer therapies or drugs to target heart disease in the press, but overall a lot less about treatments for more underserved areas. Often successful […]

October 9, 2018 - 9 minutesmins - By Helen Albert

More News! 8 Oct 2018

Cannabinoid Drugs Company Raises $300M in Public Offering

GW Pharmaceuticals, a British biotech developing cannabinoid drugs, is on a high after a successful $300M public offering on the Nasdaq Stock Market. The company announced the public offering swiftly after its lead cannabinoid drug, Epidiolex, made history by being the first cannabinoid drug to obtain approval from the FDA earlier this year. GW plans […]

October 8, 2018 - 2 minutesmins - By Jonathan Smith

Sitryx immunometabolism cancer inflammation

News and Trends 8 Oct 2018

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […]

October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 8 Oct 2018

Behind the Scenes of the Spanish Biotech Industry’s Boom

The Spanish biotech industry is booming, but from my conversations with industry players elsewhere in Europe, it seems the country’s biotech industry keeps being a mystery for many. I caught up with experts at the Biospain conference to draw an overview of how biotech in Spain is doing in 2018. When we talk about biotech […]

October 8, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2018

Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite

Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

Leuven biotech of the week wikimedia Edited

Startup Scout 5 Oct 2018

This Biotech Sticks Bacterial Proteins Together to Fight Antibiotic Resistance

This week’s biotech has its base in Leuven, Belgium. The newly-founded Aelin Therapeutics hopes to combat antibiotic resistance by doing the pharmacological equivalent of boiling an egg. Mission: To develop a new type of drugs to kill bacteria that are resistant to antibiotics. In the future, the drugs could also be used to kill pathogenic […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 4 Oct 2018

This Year’s Nobel Prizes Highlight Advances in Biotechnology

Immune system brakes, optical tweezers, and enzyme evolution. Three separate subjects that span this year’s Nobel Prizes in Physiology or Medicine, Physics and Chemistry. Despite the differences in theory, however, the diverse discoveries have one thing in common: they have applications in the biotechnology industry, Labiotech’s favorite subject. Releasing the immune system’s brakes in cancer […]

October 4, 2018 - 5 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us